We are live on ! Find out more
DFTX

Definium Therapeutics

134 hedge funds and large institutions have $327M invested in Definium Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 31 increasing their positions, 17 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,732% more capital invested

Capital invested by funds: $17.9M → $327M (+$310M)

364% more call options, than puts

Call options by funds: $28.4M | Put options by funds: $6.11M

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

246% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 13

82% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 17

72.06% more ownership

Funds ownership: 12.18%84.24% (+72%)

29% more funds holding

Funds holding: 104134 (+30)

Holders
134
Holders Change
+30
Holders Change %
+28.85%
% of All Funds
1.93%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.06%
New
45
Increased
31
Reduced
17
Closed
13
Calls
$28.4M
Puts
$6.11M
Net Calls
+$22.3M
Net Calls Change
+$16.9M

DFTX Hedge Fund Activity: Q1 2024 in Review

134 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2024, worth a combined $327M — up 1,732% from $17.9M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new DFTX positions and 13 closed out — a net gain of 32 holders — while 31 added to existing stakes and 17 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $38M. The largest seller was Ikarian Capital, cutting an estimated $1.72M.

  • 134 institutional investors held Definium Therapeutics (DFTX) as of Q1 2024, up from 104 in Q4 2023.
  • Funds reported $327M of Definium Therapeutics stock for Q1 2024, up 1,732% quarter-over-quarter.
  • 45 funds opened new Definium Therapeutics positions in Q1 2024 and 13 closed out, a net change of +32 holders.
  • The largest Definium Therapeutics buyer in Q1 2024 was Deep Track Capital, an estimated $38M added.
  • The largest Definium Therapeutics seller in Q1 2024 was Ikarian Capital, an estimated $1.72M sold.

Based on aggregated 13F filings for Q1 2024.